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1H-NMR, 1H-NMR  T2-edited, and 2D-NMR 
in bipolar disorder metabolic profiling
Sumit Sethi1, Mariana Pedrini1, Lucas B. Rizzo1, Maiara Zeni‑Graiff1, Caroline Dal Mas2, Ana Cláudia Cassinelli3, 
Mariane N. Noto1,3, Elson Asevedo1, Quirino Cordeiro3, João G. M. Pontes4, Antonio J. M. Brasil4, Acioly Lacerda1, 
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Abstract 
Background: The objective of this study was to identify molecular alterations in the human blood serum related to 
bipolar disorder, using nuclear magnetic resonance (NMR) spectroscopy and chemometrics.
Methods: Metabolomic profiling, employing 1H‑NMR, 1H‑NMR  T2‑edited, and 2D‑NMR spectroscopy and chemomet‑
rics of human blood serum samples from patients with bipolar disorder (n = 26) compared with healthy volunteers 
(n = 50) was performed.
Results: The investigated groups presented distinct metabolic profiles, in which the main differential metabolites 
found in the serum sample of bipolar disorder patients compared with those from controls were lipids, lipid metabo‑
lism‑related molecules (choline, myo‑inositol), and some amino acids (N‑acetyl‑l‑phenyl alanine, N‑acetyl‑l‑aspartyl‑
l‑glutamic acid, l‑glutamine). In addition, amygdalin, α‑ketoglutaric acid, and lipoamide, among other compounds, 
were also present or were significantly altered in the serum of bipolar disorder patients. The data presented herein 
suggest that some of these metabolites differentially distributed between the groups studied may be directly related 
to the bipolar disorder pathophysiology.
Conclusions: The strategy employed here showed significant potential for exploring pathophysiological features and 
molecular pathways involved in bipolar disorder. Thus, our findings may contribute to pave the way for future studies 
aiming at identifying important potential biomarkers for bipolar disorder diagnosis or progression follow‑up.
Keywords: 1H‑NMR, Biomarkers, Bipolar disorder, Metabolic profiling, Chemometrics, 2D NMR
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Bipolar disorder (BD) is a potentially debilitating men-
tal disorder affecting 1–3% of the population worldwide 
(Goodwin and Jamison 2007; Marohn 2011; Nierenberg 
et  al. 2013; Phillips and Kupfer 2013). Previous studies 
have suggested a number of theories to explain the eti-
ology of BD, including the influence of genetic factors, 
deficits in neurodevelopmental processes, implication of 
neurodegenerative pathologies, changes in monoamine 
neurotransmission, and abnormalities in neuroplasticity 
(van Enkhuizen et al. 2015; Goes 2016; Passos et al. 2016). 
A number of medications have been used for several dec-
ades to treat this disorder and/or to ameliorate the symp-
toms, though the mechanisms of action of most of mood 
stabilizers still remain to be fully elucidated (Malhi et al. 
2013; Yatham et  al. 2013). Increased accuracy in early 
diagnosis of BD is the key to improve the mental health 
outcomes, to ameliorate the clinical course, and to make 
better the treatment response of patients with this dis-
order. However, the diagnosis of BD, especially in early 
stages and in predominantly depressive presentations, 
remains challenging (Brietzke et  al. 2016). These chal-
lenges could possibly be overcome by the identification of 
differentially expressed biomarkers, which could reflect 
Open Access
*Correspondence:  ljubica@iqm.unicamp.br; ljubica.tasic@gmail.com; 
elisabrietzke@hotmail.com 
1 Department of Psychiatry, Universidade Federal de São Paulo‑UNIFESP, 
Rua Borges Lagoa, 570. Vila Clementino, São Paulo CEP 04038‑020, Brazil 
4 Laboratório de Química Biológica, Department of Organic Chemistry, 
Institute of Chemistry, Universidade Estadual de Campinas‑UNICAMP, 
Caixa Postal 6154, Campinas, São Paulo CEP 13083‑970, Brazil
Full list of author information is available at the end of the article
Page 2 of 9Sethi et al. Int J Bipolar Disord  (2017) 5:23 
or convey the pathophysiological processes (Oswald et al. 
2007; Marmol 2008).
Hydrogen-1 nuclear magnetic resonance (1H-NMR) 
spectroscopy-based metabolomics can be used to moni-
tor a wide range of metabolites in biological samples, 
allowing for a sensitive, high-throughput molecular 
screening (Beckonert et al. 2007). 1H-NMR has an excep-
tional reproducibility and is quantitative to the extent 
that a given peak area is directly proportional to the 
concentration of the corresponding metabolite, turning 
this technique a well-established approach for metabo-
lomics (Maher et al. 2008). Although many platforms for 
metabolic profiling (for instance, the LC–MS, GC–MS, 
NMR, capillary electrophoresis-MS) are available, none 
technology alone provides the complete coverage of the 
metabolome. Previous employment of these techniques 
to study the brain of patients with psychiatric disorders 
was reported (Lan et al. 2009; Strzelecki et al. 2015), but 
it was scarcely applied for serum metabolome studies of 
individuals with mental illnesses.
In this study, a NMR metabolomics profiling approach 
was used to identify molecular alterations in the human 
blood serum of BD patients. Our intention was to con-
duct analysis to distinguish the individuals of type 1 BD 
patients and healthy control groups, based on their meta-
bolic profiles. Also, as previously reported by us (Sus-
sulini et al. 2009), with time distance and new sampling, 
NMR-based metabolomics has been applied as to verify 




Twenty-six euthymic outpatients with bipolar disorder 
(BD) type 1 (BD group) and 50 healthy control (HC) indi-
viduals (control group) were included in the research. All 
individuals in the BD group, with age between 18 and 
65  years old, fulfilled the DSM-IV (Diagnostic and Sta-
tistical Manual of Mental Disorders) criteria according 
to SCID-I (Structured Clinical Interview for DSM Disor-
der). Euthymia was defined as not fulfill criteria for any 
mood episode and present, at the same time, with scores 
below 8 in Young Mania Rating Scale (YMRS) and Hamil-
ton Depression Rating Scale (HDRS)-17 items. Exclusion 
criteria were as follows: be acutely suicidal, comorbidity 
with substance use disorders, except nicotine, presence 
of acute or unstable or chronic general medical comor-
bidity, inability to read and understand study procedures, 
pregnancy, and postpartum period. All subjects were 
inquired on medical history, including lifetime use of any 
medication. Body mass index (BMI) was also measured 
using the formula BMI = Weight (kg)/Height (m)2.
For comparison, a control group of 50 healthy volun-
teers was recruited from the community. To be eligible 
for the HC group, individuals were required to have age 
between 18 and 65 years old, negative history of any psy-
chiatric condition current or along lifetime, and never 
made use of psychiatric medication. In addition, only vol-
unteers with no family history of major mental disorders 
(schizophrenia-spectrum disorders, mood disorders, and 
suicide) were included. The same exclusion criteria of BD 
group were applied to HC group.
Clinical assessment included SCID-I for confirmation 
of diagnosis and assessment of psychiatric comorbidi-
ties. YMRS and HDRS-17 items were used to determine 
severity of manic and depressive symptoms, respectively. 
Functioning was estimated by General Assessment of 
Functioning (GAF).
Serum collection and storage
All blood samples were taken in the morning (between 8 
and 10 a.m.) after 12 h of fasting. Blood was drawn into 
Vacutainer tubes, and immediately allowed to clot for 
at least 30 min at room temperature, before it was cen-
trifuged at 1500×g, for 5  min. The serum was then ali-
quoted, transferred into clean polypropylene tubes, and 
stored at −80 °C until use. The maximum period of stor-
age was of two weeks.
NMR spectroscopy analyses: 1H‑NMR, 1H‑NMR  T2‑edited, 
and 2D NMR
For NMR spectroscopy analyses, serum samples were 
thawed and centrifuged at 12,300×g, for 10 min, at 4 °C 
to separate any precipitate. Aliquots of 250  μL of the 
supernatants were diluted with 250  μL of deuterated 
water  (D2O) or PBS buffer (250 μL containing 10%  D2O) 
and transferred into 5.0 mm diameter NMR tubes. NMR 
tubes were placed into a Bruker 600 NMR spectrom-
eter (Bruker Advance III, Bruker GmBH, Rheinesten-
nen, Germany) using TBI (Triple resonance Broadband 
Inverse) probe at 25 °C. 1H-NMR spectra were recorded 
as three independent measurements for each sample 
using the  CH3-lactate signal (δ1.33, 3H, d, 3J =  7.0  Hz) 
as a reference, and applying the pulse sequence WATER-
GATE (p3919gp) with 128  ns (Piotto et  al. 1992). 
 T2-edited NMR spectra were recorded using the CPMG 
(Carr-Purcell-Meiboom-Gill) sequence (Meiboom and 
Gill 1958), where a fixed total spin–spin relaxation delay 
2nτ of 100 ms was used to attenuate the broad NMR sig-
nals from slowly tumbling molecules such as proteins 
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and lipids retaining those from low molecular weight 
compounds and some lipid components. For each spec-
trum, 128 transients were acquired into 32,000 data 
points, with a spectral width of 12 kHz. To confirm the 
assignments made from 1H-NMR and  T2-edited spectra, 
some blood serum samples were also examined using 2D 
 [1H–13C] HSQC. For each 2D spectrum, 256 increments 
with 64 transients per increment were collected and 
extended to 4 K data points. The signal assignments were 
based on the literature and/or databases such as Biologi-
cal Magnetic Data Bank (BMRB) (Ulrich et al. 2008) and 
Human Metabolome Database (HMDB) (Wishart et  al. 
2007) and are indicated on the  T2-edited spectrum and 
confirmed by the 2D fully assigned  [1H–13C] HSQC data.
Chemometrics of 1H NMR spectral data
1H-NMR data were transported to a data matrix, and 
chemometrics analysis, based on principal component 
analysis (PCA) and partial least-squares discriminant 
analysis (PLS-DA), were performed using MATLAB (The 
MathWorks, Natick, MA) or Pirouette (Infometrix, USA) 
software.  T2-edited spectra were not used in chemomet-
ric analysis. The spectral region of chemical shifts, from 
1.00 to 4.40 ppm, was used in chemometrics (Nørgaard 
2009). PLS-DA was used as a supervision method for 
classification (Sena et  al. 2004). All variables were auto 
scaled.
Results
The summary of the collected sample characteristics is 
presented in Table  1. A predominance of females over 
males was observed in our BD sample, and the percent-
ages were statistically different between the BD and HC 
groups. In addition, we observed, as expected, a high 
prevalence of tobacco smoking individuals in our BD 
group compared with HC group. Functioning was also 
impaired in the BD group compared with HC group, 
which reflects a well-known incomplete association 
between mood symptoms and functionality in individu-
als with BD. In addition, there was a clear predominance 
of chronic patients, with a mean duration of illness of 
about 15 years.
1H NMR spectroscopy data analysis
To explore all the potential differences in the metabolic 
profiles between the BD and HC groups, the 1H-NMR 
spectra (Fig.  1a) were subjected to PCA, i.e., the spec-
tral data obtained for 76 blood serum samples that were 
acquired as 228 spectra were used in PCA.  T2-edited 
spectra were not used in chemometrics analysis because 
Table 1 Clinical and demographic characteristics of the sample
Healthy controls (n = 50) BD (n = 26) Test
U or X2 p value
Age in years; mean (SD) 35.69 (13.03) 40.38 (12.66) 187.000 0.261
Sex female; N(%) 17 (34) 17 (65) 5.114 0.023
Ethnicitycaucasian; N(%) 18 (36) 14 (53) 0.391 0.531
Years of education; mean (SD) 12.1 (3.8) 12.4 (3.6) 181.500 0.865
BMI in kg/m2; mean (SD) 26.2 (4.43) 28.06 (7.58) 170.500 0.507
Hours of physical exercise per week; mean (SD) 1.88 (2.44) 2 (2.93) 176.500 0.949
Current smoking; N(%) 3 (11.5) 4 (23.5) 1.084 0.297
Young mania rating scale; mean (SD) 0.5 (1.06) 0.7 (1.35) 208.500 0.661
Hamilton depression rating scale; mean (SD) 1.53 (1.96) 3.23 (3.84) 167.500 0.167
General functioning assessment (symptoms); mean (SD) 88.84 (6.97) 80 (10.15) 109.500 0.004
General functioning assessment (functioning); mean (SD) 87.69 (4.52) 75.88 (16.12) 127.000 0.011
Age at onset in years; mean (SD) – 24.83 (9.83) – –
Duration of illness in years; mean (SD) – 15.44 (12.69) – –
Number of total mood episodes; mean (SD) – 9.05 (9.52) – –
Number of past manic episodes; mean (SD) – 3.38 (3.82) – –
Number of past hypomanic episodes; mean (SD) – 1.61 (4.11) – –
Number of past depressive episodes; mean (SD) – 4.05 (5.47) – –
Number of past mixed episodes; mean (SD) – 0 (0) – –
Age of diagnosis; mean (SD) – 31.16 (11.11) – –
Age of first use of psychiatric medication; mean (SD) – 26.55 (10.03) – –
Age of first use of mood stabilizer; mean (SD) – 31.58 (11.78) – –
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these spectra show altered peak areas in relation to the 
peaks of 1H-NMR spectra. Based on the PCA results, it 
was possible to observe a distinction of the samples into 
two groups: BD and HC using the spectral region δ 1.00 
to 4.40 (Fig. 2). 
Considering the PCA results and the previous observa-
tions about the spectral regions not relevant for analyses, 
PLS-DA was performed using the same spectral range 
employed in the PCA. PLS-DA of 1H NMR spectroscopy 
data revealed an excellent separation between BD and 
HC groups.
Through the assignments from 1H-NMR edited with 
 T2 filter (Fig.  1b) and the correlations from the HSQC 
contour maps (Fig.  3), it was possible to compare the 
obtained data with databases. Thereby, based mainly on 
spectral data (chemical shift, coupling constants, and 
multiplicity) and in accordance with biochemical knowl-
edge, seven key-metabolites (Fig.  4) were found to be 
crucial for the two-group separation. Furthermore, it 
was observed that there are significant differences in 
some metabolite concentrations when the two inves-
tigated groups were compared, in which important sig-
nificant variations in some metabolites were observed, 
and compounds were then identified through  T2-edited 
spectra. The blood serum samples from the BD group 
had shown to be richer in lipids, whose amounts were up 
Fig. 1 a 1H NMR Spectra with water suppression (Pulse sequence: p3919gp, ns = 128) blood serum sample from HC (black), and BD group (gray). 
Spectral region highlighted δ 4.40 to 1.00 with higher loadings. b 1H NMR Spectra recorded with  T2‑filter (Pulse sequence: cpmgpr1d, ns = 128) 
blood serum sample from HC (black), and BD group (gray). Assignments: Lactate (δ 1.33 and 4.11), glucose (δ 3.41, 3.46, 3.77 and 3.82), leucine (Leu; 
δ 1.71 and 3.73), proline (Pro; δ 3.34), glycerylphosphocholine (GPCho; δ 3.24), myo‑inositol (δ 3.25), creatine (δ 3.03), glutamine (Gln; δ 2.44), gluta‑
mate (Glu; δ 2.14), lipids (δ 1.29 and 2.04), lysine (Lys; δ 1.68), alanine (Ala; δ 1.47), valine (Val; δ 1.04)
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to 1/3 higher compared with those from the HC group. 
Also, metabolites such as d-glucose, l-alanine, and lac-
tate were more pronounced in BD group compared with 
HC group. All these metabolites were found to be more 
abundant in BD group than in HC group, as their peaks 
areas were at most presenting a ratio of about 3:2 (Addi-
tional file 1: Table S3). 
Discussion
1H-NMR-based metabolomics were used to chemomet-
ric analysis. PCA and PLS-DA analyses were employed 
to examine the metabolic profiles of blood serum of indi-
viduals with BD compared with HC volunteers. The load-
ing plot (Fig. 2) highlighted the most significant variables 
with the highest loading values, which corresponded to 
the spectral region from δ 1.00 to 4.40. The 1H-NMR 
spectra of BD blood serum samples are characterized by 
overlaps that resulted in broad and intense peaks. So, we 
acquired  T2-edited 1H-NMR spectra (Fig. 1b) to achieve a 
better spectral resolution and assign peaks referred to the 
metabolites with the low molecular weight (<1500  Da), 
such as: l-valine, l-alanine, and creatine. The peaks 
assignments were performed in comparison with chemi-
cal shifts values that were published previously (Misra 
and Bajpai 2009). It is important to mention that the 
peaks in  T2-edited spectra are not appropriate for inte-
gration. Through comparative analysis of the 2D NMR 
spectra, we observed important differences in metabolic 
profiles among serum samples from the two, BD and HC, 
groups. These differences are indicated in Fig. 3, in which 
it is possible to observe that some metabolites such as 
lipoamide, l-glutamine, among others, were detected 
only in BD group, while N-acetyl-l-alanine was observed 
only in HC group (Fig. 4).
The metabolites that had their peaks assigned based 
on the 2D NMR and that were classified as “healthy” 
means that these metabolites have a higher concentration 
in blood serum samples from the HC (healthy control) 
Fig. 2 Metabolomics discriminate bipolar disorder patients from healthy individuals. a Plots of cross‑validated PCA scores, 50 samples (25 BD + 25 
HC) is equivalent to 150 spectra (75 BD + 75 HC). b 2D samples scores plot of PLS‑DA, 76 samples (26 BD + 50 HC) is equivalent to 228 (78 
BD + 150 HC). c Loadings Graph of spectral region δ 1.00 to 4.40 used in chemometrics. d 3D samples scores plot of PLS‑DA
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group compared with the BD group individuals (Addi-
tional file 1: Table S1). The same reasoning can be applied 
to the BD group. However, it is important to remark that 
we have not quantified the identified biomarkers up to 
the present moment.
Despite the large overlapping between the peaks in 
the 1H NMR spectra, it was possible to estimate the 
concentration ratios for some metabolites, such as 
d-glucose, l-alanine, lactate, and lipids, through com-
parison of the mean value rates of peaks integration of 
Fig. 3 Two‑dimensional NMR Spectra: Contour maps of HSQC (pulse sequence: hsqcedetgpsp.3) blood serum sample from (a) HC (ns = 64, 
SD = 16), and b BD group (ns = 64, SD = 16)
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1H-NMR spectra (Additional file 1: Table S3). For com-
parison of HC and BD profiles, the greatest variation 
in concentration of metabolites was observed for the 
lipids.
Partially, our results are in accordance with numerous 
previous studies that have demonstrated changes in brain 
metabolites in BD by in  vivo 1H NMR. Davanzo et  al. 
(2001) have shown an increase in myo-inositol in anterior 
cingulate cortex in children with BD. Acute lithium(I) 
treatment was associated to a significant reduction in the 
myo-inositol/creatine ratio, especially among respond-
ers to this medication (Davanzo et  al. 2001). This result 
was also reproduced in adults (Machado-Vieira et  al. 
2015). Several other studies produced mixed results 
with choline, GABA, and glutamate, probably influenced 
by methodological issues, chosen brain areas or differ-
ences in subpopulations of individuals with the disorder 
(Bustillo 2013).
The increase of risk of hyperlipidemia in BD patients 
was reported by Hsu et  al. (2015), which corroborates 
with our results, in which increases in the lipids lev-
els in BD were also noticed (Fig. 1b). Furthermore, cur-
rently Yoshimi et al. (2016) studied the metabolism of BD 
patients through analysis of blood serum samples using 
capillary electrophoresis-time-of-flight mass spectrome-
try (CE-TOF/MS). They reported changes in amino acids 
metabolism (valine, alanine, glutamine) and metabolites 
belonging to the citric acid and urea cycles, such as the 
α-ketoglutarate and N-acetylglutamic acid whose lev-
els were increased in BD patients. In our analyses, the 
presence of α-ketoglutaric acid, α-ketoisovaleric acid 
and N-acetyl-l-aspartyl-l-glutamic acid (NAAG) was 
observed, as pointed in Fig. 4.
Glutamate and glutamine are well-known markers 
(Manji et  al. 2003). Also, Pålsson et  al. (2015) reported 
the increase in the levels of these metabolites in blood 
serum and cerebrospinal fluid (CSF) of BD patients using 
HPLC with fluorescence detection. This increase can be 
due to mitochondrial dysfunction or alterations in the 
metabolism of the cell (Hsu et al. 2015).
However, to our knowledge, the 1H-NMR spectros-
copy-based metabolomics analysis of serum was less 
studied. Sussulini et  al. (2009) investigated differential 
metabolites in human serum sample of patients with 
BD (n = 25) under different drug treatments: lithium(I) 
(n =  15) versus other medications (n =  10). This strat-
egy showed significant potential for exploring patho-
physiological and toxicological features involved in BD. 
The investigated groups (HC and patients with BD under 
different treatments) could be distinguished accord-
ing to their metabolic profiles, and the main differential 
metabolites found were glycoprotein lipids, mono- and 
polyunsaturated lipids, acetate, choline, glutamate, and 
myo-inositol.
The results of this research should be interpreted at 
light of some limitations. First, the small sample size 
precludes subgroup analysis including potential medica-
tion effects in metabolic profile. In addition, the inclu-
sion of only euthymic individuals makes impossible to 
know which metabolic changes are related to traits and 
which are related to mood states in BD. The different 
proportion of men and women between the BD and HC 
groups is a result of a female predominance in the men-
tal health service where the study was conducted. On the 
other hand, no significant differences in metabolic profile 
between female and male were noticed here. Strengths 
Fig. 4 Chemical structures of seven key‑metabolites (1 from HC group + 6 from BD group) identified by 2D NMR spectroscopy
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of the current study included the very careful selection 
of cases and controls, including the inclusion of patients 
without any significant comorbidities and HCs without 
any evidence of personal or family mental illness history.
Conclusion
Considering the main results of this study, we can con-
clude that 1H NMR spectroscopy-based metabolomics 
analysis of serum could be a useful strategy to investigate 
the pathophysiology of BD, as well as to identify and vali-
date potential biomarkers for diagnosis and/or for treat-
ment follow-up.
In this study, it was possible to the identify seven 
key-metabolites, which showed to be in accordance 
with some other works described in the literature that 
used different analytical platforms for monitoring BD. 
Although the greatest differences between the two stud-
ied groups were observed in lipid ratios (more abundant 
in the BD group), due to the overlapping, some integra-
tion of the peak areas can not be taken as sufficiently pre-
cise for quantification of some metabolites. Nevertheless, 
it is important to mention that the spectral region used 
was similar to the work of Sussulini et al. (2009) indicat-
ing a greater accuracy in this spectral range when looking 
for the biomarkers and also showing the high reproduc-
ibility of the NMR spectroscopy technique in metabo-
lomic profiling of BD individuals.
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